ATAGI recommendations on COVID-19 vaccine use in children aged 6 months to <5 years

  3 August 2022  PHN Immunisation Support Program   

The Australian Technical Advisory Group on Immunisation (ATAGI) recommends COVID-19 vaccination for children aged 6 months to <5 years with severe immunocompromise, disability, and those who have complex and/or multiple health conditions which increase the risk of severe COVID-19.

  • The recommendation is for 2 primary doses, except for those with severe immunocompromise who require 3 primary doses.
  • The recommended interval between each dose is 8 weeks.
  • A paediatric formulation of the Moderna COVID-19 vaccine (Spikevax) was provisionally approved by the Therapeutic Goods Administration (TGA) and can be used for children aged 6 months to < 5 years in the categories recommended for vaccination.

The full details of the recommendations including dosing and schedule, co-administration with other vaccines and timing following SARS-CoV-2 infection is available on the Australian Government Department of Health and Aged Care website.